vs
Side-by-side financial comparison of INSPERITY, INC. (NSP) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.7B, roughly 1.4× INSPERITY, INC.). On growth, INSPERITY, INC. posted the faster year-over-year revenue change (3.4% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $246.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -3.8%).
Insperity, Inc., previously known as Administaff, Inc., is a professional employer organization (PEO) headquartered in Kingwood, an area of Houston, Texas, USA. Insperity provides human resources and administrative services to small and medium-sized businesses. Since 2004, the company has been title sponsor of a professional golf tournament on the Champions Tour, previously known as the Administaff Small Business Classic.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
NSP vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.4B |
| Net Profit | — | $603.0M |
| Gross Margin | 10.3% | 70.2% |
| Operating Margin | -2.8% | 31.9% |
| Net Margin | — | 25.3% |
| Revenue YoY | 3.4% | 3.0% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | $-0.87 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | $2.4B | ||
| Q3 25 | $1.6B | $2.4B | ||
| Q2 25 | $1.7B | $2.5B | ||
| Q1 25 | $1.9B | $2.2B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.6B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.8B | $2.2B |
| Q4 25 | — | $603.0M | ||
| Q3 25 | $-20.0M | $721.0M | ||
| Q2 25 | $-5.0M | $718.0M | ||
| Q1 25 | $51.0M | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | $3.0M | $682.0M | ||
| Q2 24 | $18.0M | $624.0M | ||
| Q1 24 | $79.0M | $599.0M |
| Q4 25 | 10.3% | 70.2% | ||
| Q3 25 | 12.0% | 71.5% | ||
| Q2 25 | 13.4% | 73.6% | ||
| Q1 25 | 16.6% | 72.0% | ||
| Q4 24 | 13.5% | 69.5% | ||
| Q3 24 | 14.7% | 70.6% | ||
| Q2 24 | 16.2% | 71.7% | ||
| Q1 24 | 19.1% | 70.6% |
| Q4 25 | -2.8% | 31.9% | ||
| Q3 25 | -1.5% | 37.0% | ||
| Q2 25 | -0.4% | 36.7% | ||
| Q1 25 | 3.7% | 36.5% | ||
| Q4 24 | -0.9% | 31.6% | ||
| Q3 24 | 0.1% | 36.6% | ||
| Q2 24 | 1.4% | 33.0% | ||
| Q1 24 | 6.0% | 34.1% |
| Q4 25 | — | 25.3% | ||
| Q3 25 | -1.2% | 30.0% | ||
| Q2 25 | -0.3% | 29.2% | ||
| Q1 25 | 2.7% | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | 0.2% | 28.6% | ||
| Q2 24 | 1.1% | 26.4% | ||
| Q1 24 | 4.4% | 27.4% |
| Q4 25 | $-0.87 | $1.37 | ||
| Q3 25 | $-0.53 | $1.63 | ||
| Q2 25 | $-0.14 | $1.61 | ||
| Q1 25 | $1.35 | $1.41 | ||
| Q4 24 | $-0.21 | $1.29 | ||
| Q3 24 | $0.07 | $1.50 | ||
| Q2 24 | $0.48 | $1.37 | ||
| Q1 24 | $2.08 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $682.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $46.0M | $3.3B |
| Total Assets | $2.2B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $682.0M | — | ||
| Q3 25 | $521.0M | $2.1B | ||
| Q2 25 | $511.0M | $1.4B | ||
| Q1 25 | $684.0M | $1.7B | ||
| Q4 24 | $1.2B | $2.0B | ||
| Q3 24 | $596.0M | $1.7B | ||
| Q2 24 | $850.0M | $1.6B | ||
| Q1 24 | $801.0M | $2.0B |
| Q4 25 | $46.0M | $3.3B | ||
| Q3 25 | $87.0M | $5.4B | ||
| Q2 25 | $112.0M | $5.0B | ||
| Q1 25 | $119.0M | $4.7B | ||
| Q4 24 | $97.0M | $4.8B | ||
| Q3 24 | $125.0M | $5.2B | ||
| Q2 24 | $142.0M | $5.0B | ||
| Q1 24 | $140.0M | $5.1B |
| Q4 25 | $2.2B | $15.5B | ||
| Q3 25 | $2.0B | $15.2B | ||
| Q2 25 | $2.0B | $14.5B | ||
| Q1 25 | $2.1B | $14.1B | ||
| Q4 24 | $2.6B | $14.2B | ||
| Q3 24 | $1.9B | $14.4B | ||
| Q2 24 | $2.1B | $14.2B | ||
| Q1 24 | $2.1B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $255.0M | $893.0M |
| Free Cash FlowOCF − Capex | $246.0M | $732.0M |
| FCF MarginFCF / Revenue | 14.7% | 30.7% |
| Capex IntensityCapex / Revenue | 0.5% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-309.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $255.0M | $893.0M | ||
| Q3 25 | $-11.0M | $938.0M | ||
| Q2 25 | $-79.0M | $486.0M | ||
| Q1 25 | $-443.0M | $587.0M | ||
| Q4 24 | $619.0M | $905.0M | ||
| Q3 24 | $-150.0M | $951.0M | ||
| Q2 24 | $20.0M | $502.0M | ||
| Q1 24 | $31.0M | $595.0M |
| Q4 25 | $246.0M | $732.0M | ||
| Q3 25 | $-20.0M | $805.0M | ||
| Q2 25 | $-86.0M | $308.0M | ||
| Q1 25 | $-449.0M | $438.0M | ||
| Q4 24 | $606.0M | $689.0M | ||
| Q3 24 | $-164.0M | $784.0M | ||
| Q2 24 | $14.0M | $370.0M | ||
| Q1 24 | $26.0M | $455.0M |
| Q4 25 | 14.7% | 30.7% | ||
| Q3 25 | -1.2% | 33.5% | ||
| Q2 25 | -5.2% | 12.5% | ||
| Q1 25 | -24.1% | 19.7% | ||
| Q4 24 | 37.6% | 29.7% | ||
| Q3 24 | -10.5% | 32.8% | ||
| Q2 24 | 0.9% | 15.7% | ||
| Q1 24 | 1.4% | 20.8% |
| Q4 25 | 0.5% | 6.7% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | 0.4% | 7.2% | ||
| Q1 25 | 0.3% | 6.7% | ||
| Q4 24 | 0.8% | 9.3% | ||
| Q3 24 | 0.9% | 7.0% | ||
| Q2 24 | 0.4% | 5.6% | ||
| Q1 24 | 0.3% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | -8.69× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | -50.00× | 1.39× | ||
| Q2 24 | 1.11× | 0.80× | ||
| Q1 24 | 0.39× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSP
| Northeast | $455.0M | 27% |
| West | $339.0M | 20% |
| Southwest | $317.0M | 19% |
| Central | $299.0M | 18% |
| Southeast | $241.0M | 14% |
| Other Revenues | $17.0M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
